Apoptosis News and Research

RSS

Apoptosis is programmed cell death, the body's normal method of disposing of damaged, unwanted, or unneeded cells.

Prenatal processes gone awry linked to children with autism

A study by researchers at the University of California, San Diego Autism Center of Excellence shows that brain overgrowth in boys with autism involves an abnormal, excess number of neurons in areas of the brain associated with social, communication and cognitive development.

9 Nov 2011

EpiCept reports net loss of $5.4 million for third quarter 2011

EpiCept Corporation today announced operating and financial results for the three and nine months ended September 30, 2011, and provided an update with respect to the Company's key business initiatives.

8 Nov 2011

Connexin 36 protects mouse pancreatic beta-cells against immune molecules

Type 1 diabetes is a lifelong disease characterized by high levels of sugar (glucose) in the blood. It is caused by the patient's immune system attacking and destroying the cells in their pancreas that produce the hormone insulin, which regulates blood glucose levels. Surprisingly, little is known about the mechanisms regulating the sensitivity and resistance of these cells, which are known as beta-cells, to immune system attack.

7 Nov 2011

Karolinska Institute researchers discover novel cancer drug target

Vivolux AB, a drug discovery company specialized in cancer treatment, announced today that data that forms the basis for one of the company's promising projects has been published in the journal Nature Medicine. Researchers at the Karolinska Institute have discovered a novel cancer drug target.

7 Nov 2011

Senesco commences dosing in SNS01-T Phase 1b/2a clinical study for multiple myeloma

Senesco Technologies, Inc. today announced the initiation of patient dosing in its Phase 1b/2a clinical study of SNS01-T at the Mayo Clinic in Rochester, MN. The study is an open-label, multiple-dose, dose-escalation study which will evaluate the safety and tolerability of SNS01-T when administered by intravenous infusion to relapsed or refractory multiple myeloma patients.

3 Nov 2011

Nmnat1 protein may help prevent brain damage in babies with cerebral palsy

Scientists at Washington University School of Medicine in St. Louis have shown that a protein may help prevent the kind of brain damage that occurs in babies with cerebral palsy.

3 Nov 2011

First study to show how H. pylori toxin can spur apoptosis

Researchers report they have figured out how the cancer-causing bacterium Helicobacter pylori attacks a cell's energy infrastructure, sparking a series of events in the cell that ultimately lead it to self-destruct.

2 Nov 2011

AgonOx, MedImmune partner to advance OX40 agonist programs for cancer treatment

AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.

31 Oct 2011

Scientists challenge theory about why chemotherapy agents target cancer

Challenging a half-century-old theory about why chemotherapy agents target cancer, scientists at Dana-Farber Cancer Institute have devised a test that can predict how effective the drugs will be by determining whether a patient's tumor cells are already "primed" for death.

28 Oct 2011

JPO issues new patent for Genprex's lead lung cancer candidate

A new patent covering tumor suppression technologies, including the company's lead product candidate Oncoprex, was recently awarded to The University of Texas System by the Japan Patent Office. Patent number 4813746 pertains to the discovery that chromosome 3p21.3 genes act as cancer suppressors.

19 Oct 2011

Stopping necroptosis in keratinocytes prevents skin inflammation

The outer layer of the skin, called the epidermis, forms a critical physical and immunological wall that serves as the body's first line of defense against potentially harmful microorganisms. Most of the epidermis consists of cells called keratinocytes that build a mechanical barrier but also perform immune functions.

14 Oct 2011

Cylene advances preclinical development of CX-5461 for treatment of cancer

Cylene Pharmaceuticals, Inc. has advanced its targeted, non-genotoxic, activator of p53 for the treatment of leukemias, lymphomas and multiple myeloma through formal preclinical development, the Company announced today.

14 Oct 2011

EMA recommends 4SC's resminostat for orphan medicinal product designation to treat HL

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced that the European Medicines Agency (EMA) has recommended 4SC's anti-cancer compound resminostat for designation as orphan medicinal product for the treatment of Hodgkin's Lymphoma (HL), a cancer of the lymphatic system.

13 Oct 2011

NCCN Oncology Research Program wins two GSK grants

The National Comprehensive Cancer Network Oncology Research Program (ORP) has been awarded $4 million in the form of two research grants from GlaxoSmithKline (GSK) to develop studies to scientifically evaluate and define GSK2118436, a BRAF inhibitor, and GSK1120212, a MEK1 and MEK2 inhibitor. Previous research has indicated that BRAF mutations are strong targets for therapies in the treatment of advanced melanoma.

12 Oct 2011

DARA BioSciences' KRN5500 reduces neuropathic pain in patients with cancer

DARA BioSciences, Inc. today announced the Journal of Pain and Symptom Management, an internationally respected, peer-reviewed journal, has published results of a Phase II safety and efficacy study of KRN5500 for the treatment of neuropathic pain in patients with cancer.

11 Oct 2011

Study identifies three new chromosomal regions implicated in susceptibility to melanoma

The genomic analysis technologies enable the study of genetic factors related to numerous diseases. In few areas this researches brought such a big and useful volume of information as in the case of melanoma.

10 Oct 2011

CRT, Cancer Research UK establish group of scientists with expertise in lipid metabolism

Cancer Research Technology, Cancer Research UK's commercial arm, has established a group of scientists with expertise in lipid metabolism - getting energy from fats and making building blocks for cell growth - to develop targets for potential new cancer drugs.

4 Oct 2011

Plausible way to circumvent drug resistance in breast cancer cells

Breast cancer cells that mutate to resist drug treatment survive by establishing tiny pumps on their surface that reject the drugs as they penetrate the cell membrane - making the cancer insensitive to chemotherapy drugs even after repeated use.

29 Sep 2011

Researchers identify 'programmed cell death' pathway in parasitic worms

Researchers from the Walter and Eliza Hall Institute have for the first time identified a 'programmed cell death' pathway in parasitic worms that could one day lead to new treatments for one of the world's most serious and prevalent diseases.

29 Sep 2011

Enrollment complete in Spectrum Pharmaceuticals' belinostat pivotal trial for PTCL

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that it has achieved the target enrollment of the minimum of 100 evaluable relapsed or refractory peripheral T-cell lymphoma (PTCL) patients in the BELIEF registration trial.

26 Sep 2011